What is Zacks Research’s Estimate for BIO Q3 Earnings?

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Research analysts at Zacks Research dropped their Q3 2025 earnings per share (EPS) estimates for Bio-Rad Laboratories in a research report issued on Monday, September 22nd. Zacks Research analyst Team now forecasts that the medical research company will earn $2.30 per share for the quarter, down from their previous forecast of $2.42. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.81 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ FY2025 earnings at $10.02 EPS and Q3 2026 earnings at $2.61 EPS.

Several other research analysts have also recently weighed in on the stock. Wall Street Zen cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, August 22nd. Wells Fargo & Company upped their price objective on shares of Bio-Rad Laboratories from $245.00 to $265.00 and gave the stock an “equal weight” rating in a research report on Friday, August 1st. Finally, Royal Bank Of Canada upped their price objective on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an “outperform” rating in a research report on Friday, August 1st. Three equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $333.50.

Bio-Rad Laboratories Stock Down 0.3%

BIO stock opened at $282.47 on Wednesday. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17. The company’s 50 day moving average is $276.56 and its 200 day moving average is $253.03. The stock has a market cap of $7.64 billion, a price-to-earnings ratio of 24.08 and a beta of 0.95. Bio-Rad Laboratories has a 1-year low of $211.43 and a 1-year high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Thursday, July 31st. The medical research company reported $2.61 earnings per share for the quarter, beating the consensus estimate of $1.93 by $0.68. The firm had revenue of $651.60 million for the quarter, compared to analysts’ expectations of $614.82 million. Bio-Rad Laboratories had a return on equity of 4.01% and a net margin of 12.50%.The company’s revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the business posted $3.11 earnings per share. Bio-Rad Laboratories has set its FY 2025 guidance at EPS.

Institutional Trading of Bio-Rad Laboratories

Several hedge funds and other institutional investors have recently bought and sold shares of BIO. Nuveen Asset Management LLC boosted its stake in Bio-Rad Laboratories by 0.8% in the fourth quarter. Nuveen Asset Management LLC now owns 39,505 shares of the medical research company’s stock worth $12,978,000 after buying an additional 327 shares in the last quarter. ProShare Advisors LLC boosted its stake in shares of Bio-Rad Laboratories by 8.0% during the fourth quarter. ProShare Advisors LLC now owns 901 shares of the medical research company’s stock valued at $296,000 after purchasing an additional 67 shares during the period. Tidal Investments LLC boosted its stake in shares of Bio-Rad Laboratories by 21.1% during the fourth quarter. Tidal Investments LLC now owns 1,069 shares of the medical research company’s stock valued at $351,000 after purchasing an additional 186 shares during the period. Two Sigma Investments LP boosted its stake in shares of Bio-Rad Laboratories by 70.3% during the fourth quarter. Two Sigma Investments LP now owns 2,050 shares of the medical research company’s stock valued at $673,000 after purchasing an additional 846 shares during the period. Finally, Public Employees Retirement System of Ohio purchased a new stake in shares of Bio-Rad Laboratories during the fourth quarter valued at approximately $2,211,000. Hedge funds and other institutional investors own 65.24% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.